Sotyktu(deucravacitinib)

Moderate-to-severe plaque psoriasis.

1 DTP program

From $950/mo

1 platform

FDA-Approved Indications

Moderate-to-severe plaque psoriasis in adults eligible for systemic therapy

Available direct-to-patient (DTP) programs

Sorted by price, lowest first. Always verify eligibility and pricing directly with the manufacturer.

Lowest price option

via BMS Patient Connect · Bristol Myers Squibb

$950/mo

86% off $6,868 list price. Available since Jan 2026. Ships to all 50 states + Puerto Rico.

Eligibility

Valid Rx required. Cash-pay US patients. No income requirement stated.

Last verified: Mar 2026

Not sure which Sotyktu program fits your situation?